Aligos Therapeutics Presents Positive Data at APASL 2025
The original release is unavailable here.
Aligos Therapeutics, Inc. on 6ix
Story so far
- Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
- Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
- Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
Earlier from Aligos Therapeutics
- Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
- Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
- Aligos Therapeutics Announces $105 Million Private Placement Financing
- Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
- Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Later from Aligos Therapeutics
- Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025
- Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
- Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
- Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
- Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
Follow Aligos Therapeutics into a list and get an email when it puts out news.
Follow Aligos Therapeutics